BCAX Stock: Price, Earnings History and SEC Filings
Bicara Therapeutics Inc. (BCAX) last traded at $9.13, down 6.17% on the latest session and down 50.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.82 against an analyst estimate of $-0.77, a miss of 6.5%.
$9.13 -6.17%
1 month-50.94%
52-week high$30.99
52-week low$8.36
Volume4.20M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BCAX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.82 | $-0.77 | -6.49% |
| Mar 2026 | May 11, 2026 | $-0.93 | $-0.64 | -45.31% |
| Dec 2025 | Mar 30, 2026 | $-0.68 | $-0.72 | +5.56% |
| Sep 2025 | Nov 10, 2025 | $-0.67 | $-0.55 | -21.82% |
BCAX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
BCAX financial history
Net income
Free cash flow
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$138M | -$107M | – | $-2.52 |
| 2024 | – | -$68M | -$75M | – | $-4.05 |
| 2023 | – | -$52M | -$46M | – | $-89.61 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BCAX
SEC filing data is not available right now. You can search for BCAX on SEC EDGAR.
BCAX news
- Bicara Therapeutics Inc BCAXOct 30, 2026 · morningstar.com
- Analysts Offer Insights on NA Companies: Bicara Therapeutics Inc. (BCAX) and Microsoft (MSFT)Oct 27, 2026 · theglobeandmail.com
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc. (BCAX) is a US-listed public company on Nasdaq.